Performance Improvement 2011-2012. What Are the Facilitators, Barriers, Benefits and Drawbacks to Family Planning Providers' Participation in Drug Pricing and Prime Vendor Programs?


The family planning program, Title X of the Public Health Service Act, serves approximately 5 million individuals each year. The program provides contraceptive, health screening, and sexually transmitted disease prevention and treatment services. To help safety-net providers, including those supported by Title X continue to serve clients, the federal government has implemented some cost-saving mechanisms and programs. One such effort, the 340B Drug Pricing Program, requires that manufacturers provide outpatient drugs at a discounted price to certain federal grantees, including Title X-supported entities. The study researchers sought to better understand Title X providers' experiences using the programs and alternatives available to achieve pharmaceutical discounts. The research included a literature review and in-depth discussions with grantee and delegate agencies around the country currently receiving Title X funds.

Researchers found that a large portion of Title X grantees were enrolled in the 340B Program and about half of the study participants participated in the Prime Vendor program, though this proportion is increasing.

Report Title: Analysis of the Effectiveness of Title X Family Planning Providers' Use of the 340B Drug Pricing Program
Agency Sponsor: OASH, Office of the Assistant Secretary for Health
Federal Contact: Eugenia Eckard, 240-453-2831
Performer: The Lewin Group
Record ID: 9200 (Report issued October 16, 2009)

View full report


"PerformanceImprovement2011-2012.pdf" (pdf, 701.44Kb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®